FDA Approved: BRILINTA — Supplemental Application (AstraZeneca Pharmaceuticals LP)

View source ↗

Summary

FDA approved a supplemental application for Brilinta (ticagrelor) filed by AstraZeneca, resulting in a labeling update for the drug.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Coronary Syndrome
• Myocardial Infarction

Drugs mentioned

• BRILINTA (ticagrelor)

Snippet

SUPPL AP for BRILINTA (TICAGRELOR)